Skip to main content

The independent medical news service

30-01-2023 | Oncology | News | Article

EMA recommends new indication for darolutamide

Click through to find out more

Box of statins, prescription and a stethoscope

05-12-2022 | Oncology | News | Article

Statins tied to improved survival in men receiving androgen-ablative therapies

Men with advanced prostate cancer may derive a significant survival benefit from the concurrent use of statins alongside androgen-ablative therapies, suggest the Canadian authors of a systematic review and meta-analysis.

21-11-2022 | Oncology | News | Article

Add-on olaparib receives EMA backing for untreated metastatic CRPC

More details about this decision available here

04-10-2022 | Oncology | News | Article

PACE-B suggests prostate ultra-hypofractionated SBRT is ‘safe’

Ultra-hypofractionated stereotactic body radiotherapy has a low rate of side effects, similar to a standard course of conventionally or moderately hypofractionated radiotherapy for low- or intermediate-risk prostate cancer, indicate 2-year toxicity findings from the phase 3 PACE-B trial.

16-09-2022 | Oncology | News | Article

Post-prostatectomy ADT duration impacts MFS in men given radiotherapy

Long-term postoperative androgen deprivation therapy may improve metastasis-free survival versus short-term therapy in men receiving radiotherapy after radical prostatectomy for prostate cancer, research suggests.

09-09-2022 | Oncology | News | Article

Rezvilutamide benefits shown in metastatic hormone-sensitive prostate cancer

Rezvilutamide significantly delays disease progression and death relative to bicalutamide when each is combined with androgen deprivation therapy in patients with high-volume metastatic, hormone-sensitive prostate cancer, research shows.